OBSV News and Press, ObsEva SA From 02/22/19

Geneva, Switzerland and Boston, MA – February 22, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive ...

Geneva, Switzerland and Boston, MA – January 23, 2019  – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s re...

Geneva, Switzerland and Boston, MA – January 23, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reprodu...

Geneva, Switzerland and Boston – January 2, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive heal...

IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019   24-week data from Phase 2b EDELWEISS clinical trial of linzagolix in endometriosis supports 75mg without ABT and 200mg with low dose ABT for Phase 3 trials planned for 2019 &...

Introduction European biotech stocks have a lower valuation in general than American biotechs. It is an observation that many sector followers have already made. In my opinion the cause can be found in the overall ecosystem for biotech. In the United States there is more appetite for this pa...

Geneva, Switzerland and Boston, MA – November 7, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive healt...

Geneva, Switzerland and Boston, MA –October 31, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproduct...

CytomX Therapeutics (NASDAQ: CTMX ) initiated with Buy rating and $32 (68% upside) price target at H.C. Wainwright citing bullish prospects for Probody platform. More news on: CytomX Therapeutics, Rocket Pharmaceuticals, Inc., ObsEva, Healthcare stocks news, Stocks on the move, , Read ...

Geneva, Switzerland and Boston, MA – August 28, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health...